Kyowa Kirin
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kyowa Kirin sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
Kyowa Kirin: 34 sponsored US clinical trials, 1 recruiting.
Kyowa Kirin sponsors 34 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 27 completed. 8 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson's Disease, with 2 trials.
Top-decile sponsor footprint
Kyowa Kirin ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
34 total, page 1 of 1
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
NCT04014374
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
NCT04745234
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
NCT07192471
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
NCT05027646
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
NCT04190654
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
NCT03915405
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
NCT04147910
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
NCT03703102
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
NCT02915705
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT02867007
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
NCT02647866
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
NCT02750618
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
NCT02705105
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
NCT02537431
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
NCT02526160
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
NCT02304367
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
NCT02312687
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
NCT02358473
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
NCT02301130
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
NCT02163577
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
NCT01728805
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
NCT01626664
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
NCT00575562
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
NCT00346632
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
NCT00199381
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
NCT00199446
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
NCT00199433
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
NCT00199342
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
NCT00199368
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
NCT00199420
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
NCT00199407
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
NCT00955045
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
NCT00456586
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
NCT00456794
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 13 |
| Phase 3 | 8 |
What is open in the Kyowa Kirin pipeline
1 recruiting of 34 indexed (3% open); 27 completed (79%).
Phase mix: 8 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Parkinson's Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kyowa Kirin: open-pipeline peers nationwide
Peers matched on 34 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Kyowa Kirin sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 trials (± recruiting share)
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- American Regent · 34 trials · 0% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
Related
What to do with this Kyowa Kirin page
34 registered trials is a research-attention snapshot, not an endorsement of Kyowa Kirin or any single study.
- 1 of Kyowa Kirin's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinson's Disease is the condition Kyowa Kirin studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kyowa Kirin pipeline card: 34 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.